UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Check the appropriate box:
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
xDefinitive Additional Materials
¨Soliciting Material Pursuant to § 240.14a-12
Biocept, Inc.
(Exact name of registrant as specified in its charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
3. | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): |
4. | Proposed maximum aggregate value of transaction: |
5. | Total fee paid: |
7. | Form, Schedule or Registration Statement No.: |
8. | Filing Party: |
9. | Date Filed: |
EXPLANATORY NOTE
Subsequent to the filing of its definitive proxy statement with the Securities and Exchange Commission on April 30, 2015 (the “Proxy Statement”), Biocept, Inc. (the “Company”) hired Regan & Associates, Inc. to provide proxy solicitation and advisory services related to the proposals set forth in the Proxy Statement. Regan & Associates, Inc. will be paid approximately $27,500 plus out-of-pocket expenses in connection with its solicitation of proxies on behalf of the Company.